Virios Therapeutics (VIRI) Stock Price, News & Analysis

Company Overview

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Key Stats

• Today's Range: $4.75 to $5.08
• 50-Day Range: $4.50 to $5.60
• 52-Week Range: $0.13 to $1.04
• Volume: 31,130 shs
• Average Volume: 1.05 million shs
• Market Capitalization: $94.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Hold

VIRI Stock Analysis - Frequently Asked Questions

How have VIRI shares performed this year?

Virios Therapeutics' stock was trading at $2.49 at the start of the year. Since then, VIRI stock has increased by 96.5% and is now trading at $4.8920.

How were Virios Therapeutics' earnings last quarter?

Virios Therapeutics, Inc. (NASDAQ:VIRI) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02.

When did Virios Therapeutics IPO?

Virios Therapeutics (VIRI) raised $30 million in an initial public offering on Thursday, December 17th 2020. The company issued 3,000,000 shares at $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

How do I buy shares of Virios Therapeutics?

Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Virios Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Virios Therapeutics investors own include Meta Platforms (META), AMC Entertainment (AMC), SNDL (SNDL), CISO Global (CISO), Canoo (GOEV), Organigram Global (OGI).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VIRI
• CIK: 1818844
• Web: www.virios.com
• Phone: 866-620-8655
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Virios Therapeutics: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: +2.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.30 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -130.33%
• Return on Assets: -115.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.27
• Quick Ratio: 7.27

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.20 per share
• Price / Book: 24.46

Miscellaneous

• Outstanding Shares: 19,258,000
• Free Float: 16,909,000
• Market Cap: $94.21 million
• Optionable: Optionable
• Beta: 1.58